治疗下丘脑性肥胖的药物研究进展

doi:10.16352/j.issn.1001-6325.2024.05.0729

基础医学与临床 ›› 2024, Vol. 44 ›› Issue (5): 729-732.doi: 10.16352/j.issn.1001-6325.2024.05.0729

治疗下丘脑性肥胖的药物研究进展

张沥元, 杜函泽, 潘慧^*

中国医学科学院北京协和医学院北京协和医院内分泌科国家卫生健康委员会内分泌重点实验室, 北京 100730

收稿日期:2023-12-25 修回日期:2024-03-19 出版日期:2024-05-05 发布日期:2024-04-23
通讯作者: ^*panhui20111111@163.com
基金资助:
中央高水平医院临床科研专项青年项目(2022-PUMCH-A-154)

Progress in drug therapy for hypothalamic obesity

ZHANG Liyuan, DU Hanze, PAN Hui^*

Department of Endocrinology, Key Laboratory of Endocrinology of National Health Commission, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730, China

Received:2023-12-25 Revised:2024-03-19 Online:2024-05-05 Published:2024-04-23
Contact: ^*panhui20111111@163.com

摘要/Abstract

摘要： 下丘脑性肥胖(HO)是一种复杂而罕见的疾病,影响大脑中能量摄入和支出调节通路以及自主神经系统和外周激素信号的调节。目前药物治疗主要通过刺激交感神经兴奋和脂肪组织产热,从而以增加脂肪分解和能量消耗的方式抑制体质量的快速增长。此外,部分药物还可作用于大脑奖励中心,抑制HO患者过度摄食。本文介绍了外源性催产素(OXT)、芬特明/托吡酯合剂(Ph/T)、特索芬辛、赛美拉肽等新近研发药物的临床获益数据、不良反应和应用前景。

关键词: 肥胖, 脑肿瘤, 下丘脑损伤, 能量稳态, 药物治疗

Abstract: Hypothalamic obesity (HO) is a complicated and uncommon disease affecting multiple regulatory pathways of energy intake and metabolism in the brain, regulation of the autonomic nervous system and peripheral hormonal signaling. Currently, drug treatment mainly involves stimulating sympathetic nerve excitation and fat tissue thermogenesis, thereby inhibiting rapid weight gain by increasing fat breakdown and energy consumption. In addition, some drugs can also act on the reward center of the brain to inhibit excessive food intake in HO patients. This article systematically introduces the clinical benefit data, adverse reactions, and application prospects of newly developed drugs such as oxytocin (OXT), phentermine and topiramate(Ph/T), tesofensine, setmelanotide, etc.

Key words: obesity, brain tumor, hypothalamic injury, energy homeostasis, drug intervention

中图分类号:

R589.2

张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.

ZHANG Liyuan, DU Hanze, PAN Hui. Progress in drug therapy for hypothalamic obesity[J]. Basic & Clinical Medicine, 2024, 44(5): 729-732.

参考文献

[1] Lee M, Park MJ, Lee KH, et al. Obesity mechanism after hypothalamic damage: cohort analysis of neuroimaging, psychological, cognitive, and clinical phenotyping data[J]. Front Endocrinol (Lausanne), 2023, 14: 1114409. doi:10.3389/fendo.2023.1114409.
[2] Miao Y, Fan K, Peng X, et al. Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma[J]. Front Endocrinol (Lausanne), 2023, 14:1241145. doi:10.3389/fendo.2023.1241145.
[3] van Schaik J, Welling MS, de Groot CJ, et al. Dextroamphetamine treatment in children with hypothalamic obesity[J]. Front Endocrinol (Lausanne), 2022, 13:845937. doi:10.3389/fendo.2022.845937.
[4] Rydin AA, Severn C, Pyle L, et al. Novel clinical algorithm for hypothalamic obesity in youth with brain tumours and factors associated with excess weight gain[J]. Pediatr Obes, 2022, 17: e12903. doi:10.1111/ijpo.12903.
[5] Kerem L, Lawson EA. The effects of oxytocin on appetite regulation, food intake and metabolism in humans[J]. Int J Mol Sci, 2021, 22: 7737. doi:10.3390/ijms22147737.
[6] Hsu EA, Miller JL, Perez FA, et al. Oxytocin and naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection[J]. J Clin Endocrinol Metab, 2017, 103: 370-375. doi:10.1210/jc.2017-02080.
[7] McCormack SE, Wang Z, Wade KL, et al. A pilot randomized clinical trial of intranasal oxytocin to promote weight loss in individuals with hypothalamic obesity[J]. J Endocr Soc, 2023, 7: 1-16. doi:10.1210/jendso/bvad037.
[8] Hsia DS, Gosselin NH, Williams J, et al. A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity[J]. Diabetes Obes Metab, 2020, 22: 480-491. doi:10.1111/dom.13910.
[9] Son JW, Kim S. Comprehensive review of current and upcoming anti-obesity drugs[J]. Diabetes Metab J, 2020, 44: 802-818. doi:10.4093/dmj.2020.0258.
[10] Danielsson P, Janson A, Norgren S, et al. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes[J]. J Clin Endocrinol Metab, 2007, 92: 4101-4106. doi:10.1210/jc.2007-0826.
[11] Hansen HH, Hansen G, Tang-Christensen M, et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant[J]. Eur J Pharmacol, 2010, 636: 88-95. doi:10.1016/j.ejphar.2010.03.026.
[12] Huynh K, Klose M, Krogsgaard K, et al. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity[J]. Eur J Endocrinol, 2022, 186: 687-700. doi:10.1530/EJE-21-0972.
[13] Quarta C, Claret M, Zeltser LM, et al. POMC neuronal heterogeneity in energy balance and beyond: an integrated view[J]. Nat Metab, 2021, 3: 299-308. doi:10.1038/s42255-021-00345-3.
[14] Heyder NA, Kleinau G, Speck D, et al. Structures of active melanocortin-4 receptor Gs-protein complexes with NDP-α-MSH and setmelanotide[J]. Cell Res, 2021, 31: 1176-1189. doi:10.1038/s41422-021-00569-8.
[15] Wei R, Li D, Jia S, et al. MC4R in central and peripheral systems[J]. Adv Biol (Weinh), 2023, 7: e2300035. doi:10.1002/adbi.202300035.
[16] Rossi J, Balthasar N, Olson D, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis[J]. Cell Metab, 2011, 13:195-204. doi:10.1016/j.cmet.2011.01.010.
[17] Wang Y, Bernard A, Comblain F, et al. Melanocortin 4 receptor signals at the neuronal primary cilium to control food intake and body weight[J]. J Clin Invest, 2021, 131: e142064. doi:10.1172/JCI142064.
[18] Yeo GSH, Chao DHM, Siegert AM, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy[J]. Mol Metab, 2021, 48: 101206. doi:10.1016/j.molmet.2021.101206.
[19] Emet DC, Ozon A, Alikasifoglu A, et al. Alpha-melanocyte-stimulating hormone is elevated in hypothalamic obesity associated with childhood craniopharyngioma[J]. Obesity (Silver Spring), 2021, 29: 402-408. doi:10.1002/oby.23087.
[20] Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials[J]. Lancet Diabetes Endocrinol, 2020, 8: 960-970. doi:10.1016/S2213-8587(20)30364-8.
[21] Haws R, Brady S, Davis E, et al. Effect of setmelano-tide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome[J]. Diabetes Obes Metab, 2020, 22: 2133-2140. doi:10.1111/dom.14133.
[22] van Santen HM, Denzer C, Müller HL. Could setmelanotide be the game-changer for acquired hypothalamic obesity?[J]. Front Endocrinol (Lausanne), 2024, 14: 1307889. doi:10.3389/fendo.2023.1307889.
[23] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity[J]. N Engl J Med. 2022, 387: 205-216. doi:10.1056/NEJMoa2206038.
[24] Jastreboff AM, Kaplan LM, Frias JP, et al. Triple hormone-receptor agonist retatrutide for obesity-a phase 2 trial[J]. N Engl J Med. 2023, 389: 514-526. doi:10.1056/NEJMoa2301972.

治疗下丘脑性肥胖的药物研究进展

Progress in drug therapy for hypothalamic obesity

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁宝锋, 王小爽, 王芳, 余佳. 肥胖模型小鼠肝脏的病理变化及代谢组分析[J]. 基础医学与临床, 2024, 44(5): 699-704.
[2]	卢慧莹, 王建国. 下调去甲基化酶FTO抑制人肝癌细胞系HepG2增殖[J]. 基础医学与临床, 2024, 44(2): 185-191.
[3]	廖镇城, 杨思懿, 吴平安. 提高m⁶A去甲基化酶FTO表达抑制鼻咽癌细胞增殖[J]. 基础医学与临床, 2024, 44(1): 57-62.
[4]	马国英, 加孜热亚·再依拿提, 李素丽, 郭艳英. 基于血清蛋白质组学分析桥本甲状腺炎合并肥胖患者血清蛋白质差异表达[J]. 基础医学与临床, 2023, 43(9): 1375-1382.
[5]	陈辛, 陈俊, 徐幸, 王旭. 组蛋白去甲基化酶抑制剂GSK-J4减轻高脂诱导的肥胖小鼠体质量[J]. 基础医学与临床, 2023, 43(9): 1353-1358.
[6]	王鑫瑞, 秦燕. Ghrelin在代谢性疾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1299-1303.
[7]	张晶, 吴凯, 黄伟. 人前体脂肪细胞分化过程及肥胖人群脂肪组织中hsa_circ_0017650高表达[J]. 基础医学与临床, 2023, 43(7): 1079-1083.
[8]	蒋晨晨, 崔泽, 潘利, 孙纪新, 何慧婧, 胡耀达, 单广良. 河北省汉族和满族成人高血压家族史与超重/肥胖对高血压发病的交互作用[J]. 基础医学与临床, 2023, 43(7): 1053-1059.
[9]	王钰铖, 鞠瑞, 郭磊. 微课联合CBL在护理本科药物治疗学教学中的应用及评价[J]. 基础医学与临床, 2023, 43(11): 1743-1749.
[10]	李瑜, 张雯, 袁昱, 李姝亭, 王哲, 贲亚琍, 戴飏. 小鼠内源性逆转录病毒Gag抗原在胰岛的表达及单克隆抗体的制备[J]. 基础医学与临床, 2023, 43(1): 59-67.
[11]	胡诗琪, 蓝彦琦, 吴寿岭, 王晓墨, 陈朔华, 汪国栋, 王丽. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42(5): 788-794.
[12]	李妍, 刘陶迪, 周好乐. TRIB3在肥胖发生中作用的研究进展[J]. 基础医学与临床, 2021, 41(9): 1352-1355.
[13]	舒凤, 王梦伊, 张世武, 李倩竹, 张伟华. 脂肪组织炎性反应的研究进展[J]. 基础医学与临床, 2021, 41(7): 1052-1055.
[14]	许可, 胡珦, 虞伟慧, 杨丽娟, 顾雪疆. 代谢健康型肥胖与非酒精性脂肪性肝病患病率的相关性[J]. 基础医学与临床, 2021, 41(6): 837-841.
[15]	李肖肖, 边立立, 董玉明, 李娟, 刘丹丹. 月坛社区高血压患者用药及血压控制情况调查[J]. 基础医学与临床, 2021, 41(1): 93-96.